{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T15:10:31Z","timestamp":1785337831380,"version":"3.55.0"},"reference-count":38,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Solid Biosciences"},{"DOI":"10.13039\/100005693","name":"Parent Project Muscular Dystrophy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005693","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0213649","type":"journal-article","created":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T17:28:36Z","timestamp":1556731716000},"page":"e0213649","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":43,"title":["Gene therapy as a potential therapeutic option for Duchenne muscular dystrophy: A qualitative preference study of patients and parents"],"prefix":"10.1371","volume":"14","author":[{"given":"Holly","family":"Landrum Peay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janice P.","family":"Tzeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon E.","family":"Hesterlee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Strong Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Rensch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Ricotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Beaverson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8662-3353","authenticated-orcid":true,"given":"Hannah","family":"Wand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Mansfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2019,5,1]]},"reference":[{"issue":"1","key":"ref1","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1474-4422(09)70271-6","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management","volume":"9","author":"K Bushby","year":"2010","journal-title":"Lancet Neurol"},{"issue":"3","key":"ref2","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.ncl.2014.05.002","article-title":"Duchenne and Becker muscular dystrophies","volume":"32","author":"KM Flanigan","year":"2014","journal-title":"Neurol Clin"},{"issue":"1","key":"ref3","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13023-017-0631-3","article-title":"The burden, epidemiology, costs and treatment for Duchenne muscular dystrophy: an evidence review","volume":"12","author":"S Ryder","year":"2017","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"ref4","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s00415-017-8406-2","article-title":"Predictors of Health-Related Quality of Life in boys with Duchenne muscular dystrophy from six European countries","volume":"264","author":"C Otto","year":"2017","journal-title":"J Neurol"},{"issue":"6","key":"ref5","doi-asserted-by":"crossref","first-page":"e1559","DOI":"10.1542\/peds.2012-0858","article-title":"Health-related quality of life in children and adolescents with Duchenne muscular dystrophy","volume":"130","author":"K Uzark","year":"2012","journal-title":"Pediatrics"},{"issue":"5","key":"ref6","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1007\/s00415-016-8080-9","article-title":"Quantifying the burden of caregiving in Duchenne muscular dystrophy","volume":"263","author":"E Landfeldt","year":"2016","journal-title":"J Neurol"},{"issue":"5","key":"ref7","doi-asserted-by":"crossref","first-page":"e1030","DOI":"10.1542\/peds.2008-0582","article-title":"Hidden consequences of success in pediatrics: parental health-related quality of life\u2014results from the Care Project","volume":"122","author":"J Hatzmann","year":"2008","journal-title":"Pediatrics"},{"issue":"1","key":"ref8","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.pediatrneurol.2004.01.011","article-title":"Depression in parents of children with Duchenne muscular dystrophy","volume":"31","author":"MS Abi Daoud","year":"2004","journal-title":"Pediatr Neurol"},{"issue":"5","key":"ref9","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/j.1365-2524.2010.00930.x","article-title":"The effect of caregiving on women in families with Duchenne\/Becker muscular dystrophy","volume":"18","author":"A Kenneson","year":"2010","journal-title":"Health Soc Care Community"},{"issue":"1","key":"ref10","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/mus.24503","article-title":"Burden, professional support, and social network in families of children and young adults with muscular dystrophies","volume":"52","author":"L Magliano","year":"2015","journal-title":"Muscle Nerve"},{"issue":"12","key":"ref11","doi-asserted-by":"crossref","first-page":"988","DOI":"10.3109\/09638288.2011.628738","article-title":"Subjective caregiver burden of parents of adults with Duchenne muscular dystrophy","volume":"34","author":"RF Pangalila","year":"2012","journal-title":"Disabil Rehabil"},{"issue":"5","key":"ref12","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/ejhg.2015.189","article-title":"Mothers\u2019 psychological adaptation to Duchenne\/Becker muscular dystrophy","volume":"24","author":"HL Peay","year":"2016","journal-title":"Eur J Hum Genet"},{"issue":"2","key":"ref13","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s10897-015-9872-2","article-title":"Prioritizing Parental Worry Associated with Duchenne Muscular Dystrophy Using Best-Worst Scaling","volume":"25","author":"HL Peay","year":"2016","journal-title":"J Genet Couns"},{"issue":"6","key":"ref14","doi-asserted-by":"crossref","first-page":"368","DOI":"10.2146\/news170020","article-title":"Deflazacort approved for Duchenne muscular dystrophy","volume":"74","author":"K Traynor","year":"2017","journal-title":"Am J Health Syst Pharm"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.cct.2017.04.008","article-title":"Developing standardized corticosteroid treatment for Duchenne muscular dystrophy","volume":"58","author":"M Guglieri","year":"2017","journal-title":"Contemp Clin Trials"},{"issue":"1","key":"ref16","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/ana.24842","article-title":"Regarding &quot;Eteplirsen for the treatment of Duchenne muscular dystrophy&quot;","volume":"81","author":"EF Unger","year":"2017","journal-title":"Ann Neurol"},{"issue":"2","key":"ref17","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1080\/14712598.2017.1271872","article-title":"Exon skipping: a first in class strategy for Duchenne muscular dystrophy","volume":"17","author":"EH Niks","year":"2017","journal-title":"Expert Opin Biol Ther"},{"issue":"1","key":"ref18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/nat.2016.0657","article-title":"FDA Approves Eteplirsen for Duchenne Muscular Dystrophy: The Next Chapter in the Eteplirsen Saga","volume":"27","author":"A Aartsma-Rus","year":"2017","journal-title":"Nucleic Acid Ther"},{"issue":"4","key":"ref19","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/phar.1909","article-title":"Advances in the Treatment of Duchenne Muscular Dystrophy: New and Emerging Pharmacotherapies","volume":"37","author":"AM Reinig","year":"2017","journal-title":"Pharmacotherapy"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"16105","DOI":"10.1038\/ncomms16105","article-title":"Long-term microdystrophin gene therapy is effective in a canine model of Duchenne muscular dystrophy","volume":"8","author":"C Le Guiner","year":"2017","journal-title":"Nat Commun"},{"issue":"5","key":"ref21","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.ymthe.2017.02.019","article-title":"Progress toward Gene Therapy for Duchenne Muscular Dystrophy","volume":"25","author":"JR Chamberlain","year":"2017","journal-title":"Mol Ther"},{"issue":"11","key":"ref22","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1089\/hum.2004.15.1065","article-title":"Phase I study of dystrophin plasmid-based gene therapy in Duchenne\/Becker muscular dystrophy","volume":"15","author":"NB Romero","year":"2004","journal-title":"Hum Gene Ther"},{"issue":"15","key":"ref23","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJMoa1000228","article-title":"Dystrophin immunity in Duchenne\u2019s muscular dystrophy","volume":"363","author":"JR Mendell","year":"2010","journal-title":"N Engl J Med"},{"key":"ref24","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 Feb 29 -. Identifier NCT01976091, Gene Transfer Clinical Trial for LGMD2D (Alpha-sarcoglycan Deficiency) Using scAAVrh74.tMCK.hSGCA; 2013 Nov 5 [cited 2017 Aug 30]; [about 5 screens]. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01976091\" xlink:type=\"simple\">https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01976091<\/ext-link>."},{"issue":"3","key":"ref25","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3233\/JND-150083","article-title":"Follistatin Gene Therapy Improves Ambulation in Becker Muscular Dystrophy","volume":"2","author":"SA Al-Zaidy","year":"2015","journal-title":"J Neuromuscul Dis"},{"issue":"11","key":"ref26","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1038\/mt.2012.181","article-title":"Muscle function recovery in golden retriever muscular dystrophy after AAV1-U7 exon skipping","volume":"20","author":"A Vulin","year":"2012","journal-title":"Mol Ther"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/2044-5040-4-18","article-title":"NBD delivery improves the disease phenotype of the golden retriever model of Duchenne muscular dystrophy","volume":"4","author":"JN Kornegay","year":"2014","journal-title":"Skelet Muscle"},{"issue":"1","key":"ref28","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s40271-014-0104-x","article-title":"Caregiver preferences for emerging duchenne muscular dystrophy treatments: a comparison of best-worst scaling and conjoint analysis","volume":"8","author":"IL Hollin","year":"2015","journal-title":"Patient"},{"issue":"5","key":"ref29","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1002\/mus.25411","article-title":"Patient-centered benefit-risk assessment in duchenne muscular dystrophy","volume":"55","author":"IL Hollin","year":"2017","journal-title":"Muscle Nerve"},{"issue":"5","key":"ref30","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.clinthera.2014.04.011","article-title":"A community-engaged approach to quantifying caregiver preferences for the benefits and risks of emerging therapies for Duchenne muscular dystrophy","volume":"36","author":"HL Peay","year":"2014","journal-title":"Clin Ther"},{"issue":"6","key":"ref31","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.jval.2016.02.014","article-title":"Developing a patient-centered benefit-risk survey: A community-engaged process","volume":"19","author":"IL Hollin","year":"2016","journal-title":"Value Health"},{"key":"ref32","article-title":"Applied qualitative research design","author":"MR Rollin","year":"2015"},{"issue":"2","key":"ref33","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1177\/1740774517751118","article-title":"Barriers and facilitators to clinical trial participation among parents of children with pediatric neuromuscular disorders","volume":"15","author":"HL Peay","year":"2018","journal-title":"Clinical Trials"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1007\/s10897-017-0190-8","article-title":"An evidence-based, community-engaged approach to develop an interactive deliveration tool for pediatric neuromuscular trials","volume":"27","author":"RR Moultrie","year":"2018","journal-title":"Journal of Genetic Counseling"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cct.2015.11.006","article-title":"\u201cWatching time tick by\u2026\u201d: Decision making for Duchenne muscular dystrophy trials","volume":"46","author":"HL Peay","year":"2016","journal-title":"Contemporary Clinical Trials"},{"issue":"1","key":"ref36","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1177\/1740774513512726","article-title":"Expectations and experiences of investigators and parents involved in a clinical trial for Duchenne\/Becker muscular dystrophy","volume":"11","author":"HL Peay","year":"2014","journal-title":"Clinical Trials"},{"issue":"5","key":"ref37","article-title":"A community-engaged approach to quantifying caregiver preferences for the benefits and risksor emerging therapies for Duchenne muscular dystrophy","volume":"36","author":"HL Peay","year":"2014","journal-title":"Clinical Therapeutics"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Bridges JFP, Tsai JH, Janssen E, Crossnohere NL, Fischer R, Peay HL. How do members of the Duchenne and Becker muscular dystrophy community perceive a discrete-choice experiment incorporating uncertain treatment benefit? An application of research as an event. Patient. 2018.","DOI":"10.1007\/s40271-018-0330-8"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0213649","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T05:35:46Z","timestamp":1589002546000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0213649"}},"subtitle":[],"editor":[{"given":"Ramesh","family":"Narayanan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2019,5,1]]},"references-count":38,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2019,5,1]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0213649","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,1]]}}}